Teva Pharm - TEVA STOCK NEWS

Teva Pharmaceuticals announced new data on AJOVY (fremanezumab-vfrm) at the 2021 AAN Virtual Annual Meeting. The data includes 17 posters spanning long-term response in patients who initially did not respond to treatment and real-world treatment patterns. Approximately 50% of inadequate responders achieved a 50% reduction in monthly migraine days by month 15. Additionally, the study demonstrated significant reduction in acute medication claims associated with AJOVY, indicating improved treatment adherence. AJOVY remains the only long-acting anti-CGRP subcutaneous injection approved for migraine prevention in adults.

Teva Pharmaceuticals USA announced 19 presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting from April 17-22. These include data on AJOVY^® (fremanezumab) and AUSTEDO^® (deutetrabenazine). The findings emphasize AUSTEDO's safety in treating tardive dyskinesia and Huntington's disease, while AJOVY's data highlight long-term treatment efficacy. Denisa Hurtukova, VP of North America Medical Affairs, stated the commitment to enhancing patient lives with informed treatment decisions.

Teva Canada has launched a new autoinjector for AJOVY® (fremanezumab), enhancing the preventive treatment of migraines for adults experiencing at least four migraine days monthly. Previously available only in a prefilled syringe, AJOVY® now offers two latex-free formats: an autoinjector and a syringe, with flexible dosing options (225 mg monthly or 675 mg quarterly). This positions AJOVY® as the first anti-CGRP drug in Canada with multiple delivery methods. The device features a button-free mechanism and is designed for one-time use, supporting patients' needs for choice in migraine management.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its financial results for Q1 2021 on April 28, 2021, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Participants can join via specific dial-in numbers or through the company's website. Teva, a leader in generic and specialty medicines, has a diverse portfolio of over 3,500 products, serving around 200 million people globally. The company cautions that forward-looking statements in the upcoming call may involve risks that could affect future performance.

Teva Canada has enhanced its Caregiver-Friendly Pharmacy (CFP) program by introducing new mental health support resources for caregivers, recognizing the pandemic's toll on them. Launched on National Caregiver Day, these resources underscore the pivotal role of Canada's eight million unpaid caregivers. Teva's research highlights that 43% of the global population identifies as caregivers, yet many lack adequate support. Key offerings include a partnership with Huddol for a resilience-building class and a 30-day free trial of the Huddol Journeys App, aiming to empower caregivers in their challenging roles.

Teva Pharmaceuticals USA has launched the first generic version of AZOPT (brinzolamide ophthalmic suspension) 1%, approved by the FDA to treat ocular hypertension and open-angle glaucoma. This product provides patients with an affordable treatment option, with annual U.S. sales over $184 million. Teva holds the largest FDA-approved generic portfolio, with nearly 550 products available. This launch demonstrates Teva's commitment to expanding access to essential medicines while maintaining a leading position in the generics market.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that CFO Eli Kalif will present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference on March 2, 2021, at 8:30 a.m. Eastern Time. Investors can access a live webcast on Teva’s Investor Relations website. An archived presentation will be available shortly after the session. Teva, a leader in generic and specialty medicines, has over 3,500 products serving approximately 200 million people globally daily. For more information, visit www.tevapharm.com.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has published an in vitro study in Cephalalgia examining the differences in mechanisms between various CGRP-targeting drugs. The study indicates that AJOVY (fremanezumab) selectively targets the CGRP ligand, while other therapies may bind to multiple receptors, potentially leading to off-target effects. The research highlights significant biological variances in targeting CGRP ligands versus receptors, though clinical implications remain uncertain. AJOVY is the first long-acting anti-CGRP injection approved in the U.S. and EU for migraine prevention.

Teva Pharmaceutical Industries Ltd. reported Q4 and FY 2020 results, with Q4 revenues at $4.5 billion and FY 2020 revenues at $16.7 billion. Key highlights include non-GAAP EPS of $0.68 for Q4 and $2.57 for FY 2020. The company anticipates 2021 revenue between $16.4 billion and $16.8 billion, with non-GAAP EPS projected between $2.50 and $2.70. Despite experiencing a 1% revenue decline from 2019, gross profit increased by 3%, attributed to higher sales from AUSTEDO and AJOVY. Teva also reported cash flow from operations of $1.216 billion in 2020.